MGTX Logo

MeiraGTx Holdings plc (MGTX) Stock Forecast & Price Prediction

Live MGTX Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$6.70

+0.10 (1.52%)

12 Month Price Forecast For MGTX

$6.70
Current Price
$523.63M
Market Cap
5 Ratings
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to MGTX Price Forecasts

+437.3%
To High Target of $36.00
+198.5%
To Median Target of $20.00
+64.2%
To Low Target of $11.00

MGTX Price Momentum

-1.6%
1 Week Change
+17.3%
1 Month Change
+5.7%
1 Year Change
+10.0%
Year-to-Date Change
-9.1%
From 52W High of $7.37
+74.0%
From 52W Low of $3.85

๐Ÿค” Considering MeiraGTx (MGTX)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 6:03 PM UTC

MGTX Analyst Ratings & Price Targets

Based on our analysis of 6 Wall Street analysts, MGTX has a bullish consensus with a median price target of $20.00 (ranging from $11.00 to $36.00). Currently trading at $6.70, the median forecast implies a 198.5% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Daniil Gataulin at Chardan Capital, projecting a 437.3% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 64.2% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MGTX Analyst Consensus

5
Buy
0
Hold
0
Sell

MGTX Price Target Range

Low
$11.00
Average
$20.00
High
$36.00
Current: $6.70

Latest MGTX Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MGTX.

Date Firm Analyst Rating Change Price Target
Nov 18, 2024 Chardan Capital Daniil Gataulin Buy Maintains $36.00
Nov 14, 2024 RBC Capital Luca Issi Outperform Maintains $11.00
Aug 13, 2024 RBC Capital Luca Issi Outperform Maintains $9.00
Jul 31, 2024 Chardan Capital Daniil Gataulin Buy Maintains $36.00
Mar 15, 2024 RBC Capital Luca Issi Outperform Reiterates $11.00
Aug 11, 2023 Chardan Capital Geulah Livshits Buy Reiterates $41.00
Aug 11, 2023 RBC Capital Luca Issi Outperform Maintains $11.00
May 12, 2023 Piper Sandler Christopher Raymond Overweight Maintains $25.00
Mar 16, 2023 Chardan Capital Geulah Livshits Buy Maintains $41.00
Mar 15, 2023 RBC Capital Luca Issi Outperform Maintains $22.00
Aug 12, 2022 Chardan Capital Geulah Livshits Buy Maintains $47.00
May 13, 2022 Chardan Capital Geulah Livshits Buy Maintains $46.00
May 13, 2022 Barclays Gena Wang Overweight Maintains $18.00
Oct 23, 2020 RBC Capital Outperform Initiates $0.00
Sep 3, 2019 Piper Sandler Overweight Initiates $0.00
Sep 3, 2019 Piper Jaffray Overweight Initiates $0.00
Jul 9, 2018 Evercore ISI Group Outperform Initiates $0.00
Jul 3, 2018 Barclays Overweight Initiates $0.00

Stocks Similar to MeiraGTx Holdings plc

The following stocks are similar to MeiraGTx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

MeiraGTx Holdings plc (MGTX) Financial Data

MeiraGTx Holdings plc has a market capitalization of $523.63M with a P/E ratio of -4.5x. The company generates $13.93M in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is +113.8% quarter-over-quarter, while maintaining an operating margin of -367.0% and return on equity of -94.0%.

Valuation Metrics

Market Cap $523.63M
Enterprise Value $487.49M
P/E Ratio -4.5x
PEG Ratio 8.1x
Price/Sales 37.6x

Growth & Margins

Revenue Growth (YoY) +113.8%
Gross Margin -9.9%
Operating Margin -367.0%
Net Margin 0.0%
EPS Growth +113.8%

Financial Health

Cash/Price Ratio +23.5%
Current Ratio 2.3x
Debt/Equity 90.6x
ROE -94.0%
ROA -38.9%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

MeiraGTx Holdings plc logo

MeiraGTx Holdings plc (MGTX) Company Overview

About MeiraGTx Holdings plc

What They Do

Develops gene therapies for serious diseases.

Business Model

MeiraGTx Holdings operates as a clinical-stage gene therapy company, focusing on developing innovative treatments for serious diseases, particularly ocular and neurodegenerative diseases. The company generates revenue through collaborations, such as its partnership with Janssen Pharmaceuticals, and through the advancement of its clinical programs, which may lead to eventual product commercialization.

Additional Information

Founded in 2015 and headquartered in New York, MeiraGTx is involved in multiple clinical trials, including therapies for achromatopsia and Parkinson's disease. Its focus on rare genetic disorders positions it in a niche but potentially lucrative market, appealing to investors interested in biotech innovations.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

387

CEO

Dr. Alexandria Forbes Ph.D.

Country

United States

IPO Year

2018

MeiraGTx Holdings plc (MGTX) Latest News & Analysis

MGTX stock latest news image
Quick Summary

MeiraGTx has obtained Rare Pediatric Disease Designation for four inherited retinal diseases, highlighting its proprietary technology's therapeutic potential.

Why It Matters

MeiraGTx's RPDD for four IRDs enhances its market positioning, potentially attracting investment and partnerships, and may lead to expedited development and commercialization of their therapies.

Source: GlobeNewsWire
Market Sentiment: Neutral
MGTX stock latest news image
Quick Summary

MeiraGTx Holdings plans a near-term BLA filing for AAV-AIPL1 in the UK for Leber congenital amaurosis 4 and anticipates a 2025 filing for Bota-vec for X-linked Retinitis Pigmentosa. Phase 3 study for AAV-GAD in Parkinson's is set for 2025.

Why It Matters

MeiraGTx's advancements in gene therapies and upcoming BLA filings signal potential revenue growth and market expansion, impacting stock performance and investor sentiment.

Source: Seeking Alpha
Market Sentiment: Positive
MGTX stock latest news image
Quick Summary

MeiraGTx Holdings plc's stock rose over 40% after positive Parkinson's disease data. The company has a diverse gene therapy pipeline and expects multiple BLAs from 2024-2027, supported by deals with J&J and Sanofi.

Why It Matters

MeiraGTx's 40% rally reflects strong investor confidence driven by positive Parkinson's data, strategic partnerships, and a promising pipeline, indicating potential for significant future returns.

Source: Seeking Alpha
Market Sentiment: Positive
MGTX stock latest news image
Quick Summary

MeiraGTx Holdings PLC (MGTX) reported a quarterly loss of $0.54 per share, worse than the expected loss of $0.47, improving from a loss of $0.74 per share a year prior.

Why It Matters

MeiraGTx's larger-than-expected quarterly loss may signal ongoing financial challenges, impacting investor confidence and stock performance amid year-over-year improvement.

Source: Zacks Investment Research
Market Sentiment: Negative
MGTX stock latest news image
Quick Summary

MeiraGTx (MGTX) experienced significant trading volume recently, but recent earnings estimate revisions may hinder its upward momentum in the near term.

Why It Matters

Higher trading volume in MeiraGTx signals increased interest, but negative earnings estimate revisions could indicate potential declines, affecting investor sentiment and stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
MGTX stock latest news image
Quick Summary

MeiraGTx stock increased by 15% after its gene therapy candidate showed superior results compared to a sham treatment in patients with Parkinson's disease.

Why It Matters

MeiraGTx's stock surge indicates strong investor confidence in its gene therapy's efficacy, potentially leading to increased market share and future revenue in the Parkinson's treatment sector.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About MGTX Stock

What is MeiraGTx Holdings plc's (MGTX) stock forecast for 2025?

Based on our analysis of 6 Wall Street analysts, MeiraGTx Holdings plc (MGTX) has a median price target of $20.00. The highest price target is $36.00 and the lowest is $11.00.

Is MGTX stock a good investment in 2025?

According to current analyst ratings, MGTX has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.70. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MGTX stock?

Wall Street analysts predict MGTX stock could reach $20.00 in the next 12 months. This represents a 198.5% increase from the current price of $6.70. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is MeiraGTx Holdings plc's business model?

MeiraGTx Holdings operates as a clinical-stage gene therapy company, focusing on developing innovative treatments for serious diseases, particularly ocular and neurodegenerative diseases. The company generates revenue through collaborations, such as its partnership with Janssen Pharmaceuticals, and through the advancement of its clinical programs, which may lead to eventual product commercialization.

What is the highest forecasted price for MGTX MeiraGTx Holdings plc?

The highest price target for MGTX is $36.00 from Daniil Gataulin at Chardan Capital, which represents a 437.3% increase from the current price of $6.70.

What is the lowest forecasted price for MGTX MeiraGTx Holdings plc?

The lowest price target for MGTX is $11.00 from Luca Issi at RBC Capital, which represents a 64.2% increase from the current price of $6.70.

What is the overall MGTX consensus from analysts for MeiraGTx Holdings plc?

The overall analyst consensus for MGTX is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.

How accurate are MGTX stock price projections?

Stock price projections, including those for MeiraGTx Holdings plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.